trending Market Intelligence /marketintelligence/en/news-insights/trending/YycYngmyxX1_QMLpWOSm0g2 content esgSubNav
In This List

US FDA approves Novo Nordisk's drug for hemophilia B

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA approves Novo Nordisk's drug for hemophilia B

The U.S. FDA approved the biologics license application for Novo Nordisk A/S' REBINYN, a drug to treat adults and children with hemophilia B, a blood clotting disorder.

Novo Nordisk plans to launch the drug in the U.S. during the first half of 2018.